Status epilepticus, defined as a seizure lasting longer than 30 minutes or intermittent seizures lasting longer than 30 minutes from which the patient does not regain consciousness, occurs in up to 60,000 people in the US annually, with the highest incidence in very young children and in adults older than 60 years. About one third of cases present as the initial seizure of developing epilepsy, one third in patients with previous diagnoses of epilepsy, and one third at the time of an acute isolated brain insult. Status epilepticus is not a benign event; recent studies indicate mortality rates ranging from 8% to 32%, and a mortality rate as high as 50% has been reported Early control of acute seizures in children is a primary goal of emergent therapy. Cessation of seizure activity not only reduces the chance of injury and the long-term morbidity associated with recurrent seizures, but also may decrease the probability of seizure recurrence. Acute seizures are treated pharmacologically, and optimal drug therapy depends on a number of variables, including the choice of anticonvulsant agent, the route of administration, the dose, and the potential adverse effects of individual agents and combinations of agents. We convened a multidisciplinary panel of experts and conducted a roundtable on the Management of Acute Seizures in Children on December 5, 1997, in Boston, Massachusetts, to discuss these issues. We had initially thought the roundtable would provide the basis of a consensus statement, but the proceedings ultimately proved worthy of a supplement. We hope child neurologists and all those who treat seizures in children will take advantage of this novel format for continuing medical education by completing the continuing medical education posttest at the end of this publication.
Status epilepticus, defined as a seizure lasting longer than 30 minutes or intermittent seizures lasting longer than 30 minutes from which the patient does not regain consciousness, occurs in up to 60,000 people in the US annually, with the highest incidence in very young children and in adults older than 60 years. About one third of cases present as the initial seizure of developing epilepsy, one third in patients with previous diagnoses of epilepsy, and one third at the time of an acute isolated brain insult. Status epilepticus is not a benign event; recent studies indicate mortality rates ranging from 8% to 32%, and a mortality rate as high as 50% has been reported Early control of acute seizures in children is a primary goal of emergent therapy. Cessation of seizure activity not only reduces the chance of injury and the long-term morbidity associated with recurrent seizures, but also may decrease the probability of seizure recurrence. Acute seizures are treated pharmacologically, and optimal drug therapy depends on a number of variables, including the choice of anticonvulsant agent, the route of administration, the dose, and the potential adverse effects of individual agents and combinations of agents. We convened a multidisciplinary panel of experts and conducted a roundtable on the Management of Acute Seizures in Children on December 5, 1997, in Boston, Massachusetts, to discuss these issues. We had initially thought the roundtable would provide the basis of a consensus statement, but the proceedings ultimately proved worthy of a supplement. We hope child neurologists and all those who treat seizures in children will take advantage of this novel format for continuing medical education by completing the continuing medical education posttest at the end of this publication.
In the first paper, Solomon L. Moshé, MD, reviews the reported relationship between seizures early in life and the subsequent development of hippocampal damage leading to intractable temporal lobe epilepsy in late childhood or in adulthood. He concludes that the predominance of available data indicate that such seizure-induced hippocampal damage may be age-and etiology-specific, and that additional basic science and clinical studies are needed to appreciate the neurobiology of this relationship.
The clinical presentation of acute seizures in the emergency department is discussed by Thomas E. Terndrup, MD. He notes that febrile convulsions or exacerbations of underlying seizure disorders predominate, while new-onset epilepsy or other seizure disorders account for a smaller proportion of cases. Acute management in the emergency department is a key area for practice refinement. Because of the way Dr Temdrup sees patients, his views differ somewhat from those of child neurologists. His findings on respiratory compromise from his investigations in animals with seizures are new and of great importance. James W. Wheless, MD, addresses the use of intravenous phenytoin and disadvantages of intramuscular phenytoin in the treatment of acute pediatric seizures. Appropriate dosing for neonates and children was not determined until the pharmacokinetics of phenytoin were established. A number of the adverse effects of phenytoin can be linked to this agent's high pH value and the presence of propylene glycol as a diluent.
Lloyd E. Knapp, PharmD, and Alan R. Kugler, PhD, review clinical experience with fosphenytoin in adults. Fosphenytoin is a prodrug of phenytoin formulated without the high pH value and organic solvents required for parenteral phenytoin. For this reason, Dr Knapp and Dr Kugler note fosphenytoin is significantly better tolerated during and after intravenous or intramuscular administration.
The clinical experience with fosphenytoin in children is presented by Lawrence Morton, MD. Unlike phenytoin, fosphenytoin can be administered intravenously in a variety of diluents. Dr Morton points out that the pharmacokinetics of fosphenytoin are similar in children and adults. No serious adverse events were encountered among 78 pediatric patients treated with fosphenytoin in clinical trials.
E. Martina Bebin, MD, reviews other treatment modalities for acute seizures in children. She observes that most acute seizures will respond to initial treatment with a benzodiazepine if adequate medication is administered. Other agents include phenytoin, fosphenytoin, and phenobarbital. Drug selection should be based on the agent's onset of action, spectrum of antiseizure activity, route and ease of administration, elimination half-life, therapeutic margin of safety, and redistribution from the central nervous system. Lastly, Nina Graves, PharmD, discusses pharmacoeconomic considerations in treatment options for acute seizures. S2 She reports that rectal diazepam provides a pharmacoeconomic benefit by reducing emergency department costs despite the cost of the drug. Similarly, when all aspects of treatment are considered, fosphenytoin provides a substantial pharmacoeconomic benefit compared with phenytoin.
Joining the presenters at the roundtable were several other experts in the fields of neurology, pediatrics, pharmacology, and emergency medicine. Highlights of their lively discussions are also included in this supplement. The panel did not reach unanimity on all issues regarding the evaluation and treatment of children with acute seizures. Nevertheless, all participants perceived acute seizures as a true emergency and agreed on the need for rapid assessment and safe and effective treatment. A rational protocol for inpatient and outpatient management of acute seizures is strongly recommended, and it is suggested that readers carefully examine their settings to see if such a protocol has been established.
This important scientific and clinical information has been provided in journal supplement format with an accompanying evaluation and CME post-test. We estimate it will require approximately 4 hours to read the articles, review the post-test questions, and complete the written test and evaluation.
We hope you find this publication interesting, clinically relevant, thought-provoking, and a valuable vehicle for pursuing continuing medical education. On behalf of the participants, I would like to thank the Medical College of Virginia of Virginia Commonwealth University for providing CME sponsorship and Parke-Davis for providing an unrestricted educational grant to support the roundtable and supplement.
